Table 2.
Comparison of Baseline Characteristics: Laboratory Findings and 6‐Month Clinical Outcomes Between Patients With High and Low MPO Levels of the Second Blood Sample
| MPO ≤306.3 pmol/L, n = 396 | MPO >306.3 pmol/L, n = 267 | P Value | |
|---|---|---|---|
| Age, y, mean ± SD | 63.7 ± 13.0 | 65 ± 12 | 0.199 |
| Male gender | 69.7% (276) | 68.9% (184) | 0.83 |
| Body mass index | 28 ± 4 | 27 ± 4 | 0.483 |
| Hypertension | 70.9% (280) | 67.8% (181) | 0.722 |
| Hypercholesterolemia | 44.8% (177) | 37.5% (100) | 0.06 |
| Diabetes mellitus | 19.2% (76) | 23.6% (63) | 0.177 |
| Currently smoking | 32.9% (130) | 33% (88) | 0.99 |
| ACS family history | 20.5% (81) | 17.2% (46) | 0.293 |
| Previous MI | 11.6% (46) | 11.3% (30) | 0.885 |
| Previous PCI | 12.2% (48) | 11.7% (31) | 0.847 |
| Previous CABG | 5.8% (23) | 6.8% (18) | 0.622 |
| Angina pectoris | 92.9% (367) | 87.6% (233) | 0.21 |
| STEMI | 42.5% (168) | 42.5% (113) | 0.99 |
| Cardiogenic shock | 0.3% (1) | 3.8% (10) | 0.001 |
| Blood sampling time, h | 31.8 ± 20.4 | 30.4 ± 19.6 | 0.633 |
| ACS negative | 11.6% (46) | 9.8% (26) | 0.449 |
| PCI | 78.7% (311) | 76.7% (204) | 0.535 |
| CABG | 2% (8) | 7.1% (19) | 0.001 |
| 6‐Month mortality | 3.5% (14) | 9.1% (24) | 0.003 |
| Reinfarction | 0.8% (3) | 1.9% (5) | 0.195 |
| MACE | 3.8% (16) | 10.9% (29) | 0.001 |
| LVEF, % | 50 ± 12 | 47 ± 12 | 0.274 |
| Troponin I, >0.05 ng/mL | 72.5% (287) | 81.3% (217) | 0.009 |
| MPO, pmol/L | 162.7 ± 67.0 | 1775.1 ± 2627.9 | <0.0001 |
Abbreviations: ACS, acute coronary syndrome; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MPO, myeloperoxidase; PCI, percutaneous coronary intervention; SD, standard deviation; STEMI, ST‐elevation myocardial infarction.
Data are mean ± SD or % (no.) of patients. Continuous variables were analyzed using the Wilcoxon rank sum test. Categorical variables were analyzed by using the χ2 test or Fisher exact test.